Xeris Biopharma Holdings, Inc. XERS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 85.9%+3.7pp | 85.4%+3.6pp | 84.6%+3.2pp | 82.2%-1.5pp | 82.2%-0.7pp | |
| Operating margin | 11.4%+22.3pp | 8.5%+25.9pp | 3.1%+27.2pp | -4.7%+15.8pp | -10.9%+15.4pp | |
| Net margin | 3.8%+24.1pp | 0.2%+27.2pp | -5.9%+27.8pp | -13%+19.8pp | -20.3%+17.3pp | |
| EBITDA margin | 11.8%+22.1pp | 9%+25.8pp | 3.5%+27.0pp | -4.2%+15.6pp | -10.3%+15.1pp | |
| Returns | ||||||
| Return on assets | 3.4%+17.2pp | 0.2%+17.1pp | -4.5%+14.9pp | -9.6%+8.4pp | -13.8%+5.8pp | |
| Return on invested capital | 21.4%+34.4pp | 15%+36.8pp | 4.7%+29.1pp | -6.2%+13.1pp | -13%+11.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.9×+0.2× | 0.8×+0.2× | 0.8×+0.2× | 0.7×+0.2× | 0.7×+0.2× | |
| Inventory turnover | 0.7×-0.1× | 0.7×-0.1× | 0.7×-0.1× | 0.8×0.0× | 0.8×0.0× | |
| Liquidity | ||||||
| Current ratio | 2.1×+0.4× | 2.2×+0.5× | 1.9×+0.1× | 1.9×-0.3× | 1.7×-0.7× | |
| Quick ratio | 1.5×+0.3× | 1.6×+0.4× | 1.3×+0.1× | 1.2×-0.4× | 1.2×-0.6× | |
| Cash ratio | 0.9×+0.3× | 1×+0.3× | 0.8×+0.1× | 0.6×-0.1× | 0.6×-0.2× | |
| Leverage | ||||||
| Debt-to-equity | 19.9×— | 18.9×— | —— | —— | —— | |
| Debt-to-assets | 0.7×-0.2× | 0.7×-0.2× | 0.7×-0.1× | 0.8×0.0× | 0.9×+0.1× | |
| Net debt / EBITDA | 3.9×— | 5.6×— | 17.6×— | —— | —— | |
| Interest coverage | 1.3×+2.0× | 0.9×+2.0× | 0.3×+1.8× | -0.4×+0.9× | -0.8×+0.9× | |
| Per Share | ||||||
| Book value per share | $0.07+132% | $0.08+139% | -$0.00+97.5% | -$0.12+6.8% | -$0.23-253% | |
| Valuation | ||||||
| Market capitalization | $1.28B+76.9% | $1.3B+158% | $1.31B+211% | $746.32M+136% | $845.13M+178% | |
| Enterprise value | $1.42B+52.7% | $1.45B+106% | $1.48B+133% | $944.26M+78.7% | $1.06B+107% | |
| Price / earnings | 106.4×— | 2,351.1×— | —— | —— | —— | |
| Price / sales | 4.1×+0.8× | 4.5×+2.0× | 4.9×+2.7× | 3×+1.3× | 3.8×+2.0× | |
| Price / book | 98.2×— | 95.1×— | —— | —— | —— | |
| EV / EBITDA | 38.3×— | 55.3×— | 157.3×— | —— | —— | |
| EV / sales | 4.5×+0.3× | 5×+1.5× | 5.6×+2.2× | 3.8×+0.9× | 4.7×+1.8× | |
| Earnings yield | 0.9%+7.2pp | 0%+10.9pp | -1.2%+13.7pp | -4.3%+14.6pp | -5.3%+15.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Xeris Biopharma Holdings, Inc.'s profit margins?
- Xeris Biopharma Holdings, Inc. (XERS) runs a 85.9% gross margin and a 11.4% operating margin, with a 3.8% net margin.
- Where do Xeris Biopharma Holdings, Inc.'s ratios come from?
- Every ratio is computed from Xeris Biopharma Holdings, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
